Evidence map›Paper›PMID 41313016›Full record

ArticlemSphere2025

Analysis of the drug target of the anti-tuberculosis compound OCT313: phosphotransacetylase is a potential drug target for anti-mycobacterial agents.

Takemasa Takii, Tomohiro Hasegawa, Saotomo Itoh, Shinji Maeda, Takayuki Wada, Yasuhiro Horita, Akihito Nishiyama, Sohkichi Matsumoto, Naoya Ohara, Aoi Kimishima and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Takemasa TakiiDepartment of Mycobacterium Reference and Research, the Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Kiyose, Tokyo, Japan.ORCID 0000-0002-5005-0941
Tomohiro HasegawaDepartment of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi, Japan.
Saotomo ItohDepartment of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi, Japan.
Shinji MaedaGraduate School of Pharmaceutical Sciences, Hokkaido University of Sciences, Sapporo, Hokkaido, Japan.
Takayuki WadaDepartment of Microbiology, Graduate School of Human Life and Ecology, Osaka Metropolitan University, Osaka, Japan.
Yasuhiro HoritaDepartment of Clinical Pharmaceutics, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Aichi, Japan.
Akihito NishiyamaDepartment of Bacteriology, Niigata University School of Medicine, Niigata, Japan.
Sohkichi MatsumotoDepartment of Bacteriology, Niigata University School of Medicine, Niigata, Japan.ORCID 0000-0002-6106-7538
Naoya OharaDepartment of Oral Microbiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Aoi KimishimaLaboratory of Applied Microbial Chemistry, Ōmura Satoshi Memorial Institute, Kitasato University, Minato-ku, Tokyo, Japan.
Yukihiro AsamiLaboratory of Applied Microbial Chemistry, Ōmura Satoshi Memorial Institute, Kitasato University, Minato-ku, Tokyo, Japan.
Shigeaki HidaDepartment of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi, Japan.
Kikuo OnozakiDepartment of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi, Japan.

Funding

Japan Agency for Medical Research and Development JP21fk0108590, JP23fk0108591, JP223fa627005Japan Society for the Promotion of Science 20K07125, 24K09872
6 · The paper itself

Abstract

Tuberculosis (TB) is one of the most common infectious diseases caused by bacteria worldwide. The increasing prevalence of multidrug-resistant TB (MDR-TB) and latent TB infection (LTBI) has intensified the global TB burden. Therefore, the development of new drugs for MDR-TB and LTBI is urgently required. We have reported that the derivative of dithiocarbamate sugar derivative, 2-acetamido-2-deoxy-β-D-glucopyranosyl

Indexed as

Antitubercular AgentsMycobacterium tuberculosisPhosphate AcetyltransferaseAnimalsBacterial ProteinsHumansMicrobial Sensitivity TestsMutationTuberculosis, Multidrug-ResistantAntitubercular AgentsBacterial ProteinsPhosphate Acetyltransferaseacetyl coenzyme Aanti-mycobacterial agentsdithiocarbamatelatent tuberculosis infectionN-acetyl glucosaminephosphotransacetylase

Identifiers

PMID41313016
PMCPMC12724200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.